Table 1.
Clinical characteristics of the study population
| Clinical characteristics | Total (n = 93) | HD (n = 43) | PD (n = 50) | P-value |
|---|---|---|---|---|
| Mean age, years (range) | 51.6 (23–74) | 52.8 (31–74) | 50.6 (23–72) | 0.41 |
| Gender (Male : Female) | 43:50 | 19:24 | 24:26 | 0.71 |
| BMI, kg/m2, mean ± SD | 23.0 ± 3.7 | 22.6 ± 3.1 | 23.3 ± 4.3 | 0.44 |
| Cause for ESRD | ||||
| DM | 34 (36.6) | 19 (44.2) | 15 (30.0) | 0.23 |
| HTN | 44 (47.3) | 19 (44.2) | 25 (50.0) | 0.73 |
| aOthers | 15 (16.1) | 5 (11.6) | 10 (20.0) | 0.66 |
| Use of steroid | 2 (2.2) | 1 (2.3) | 1 (2) | 1.0 |
| Previous TB treatment (%) | 0 (0) | 0 (0) | 0 (0) | 1.0 |
| Presence of BCG scar (%) | 62/93 (66.7) | 19/43 (44.2) | 43/50 (86.0) | 0.001 |
| Baseline QFT-IT + (%) | 39/93 (41.9) | 19/43 (44.2) | 20/50 (40.0) | 0.68 |
| 2nd QFT-IT + (%) | 32/93 (34.4) | b19/43 (44.2) | 13/50 (26.0) | 0.07 |
| Old TB lesion (%) | 35/93 (37.6) | 14/43 (32.6) | 21/50 (42.0) | 0.35 |
| LTBI treatment among initial QFT-IT + (%) | 18/39 (46.2) | 5/19 (26.3) | 13/20 (65.0) | 0.02 |
| Isoniazid: Rifampicin | 10:8 | 3:2 | 7:6 | 1.0 |
aOthers include autoimmune diseases, glomerulonephritis, polycystic kidney diseases, and unknown diseases
bOne of 19 patients showed conversion from negative to positive result
HD Hemo-dialysis, PD peritoneal dialysis, BMI body mass index, TB tuberculosis, LTBI latent TB infection, BCG bacille Calmette-Guérin, QFT-IT QuantiFERON-TB Gold In-Tube, SD standard deviation